



Tuesday
20 April 2021

| | |
|--------------------------|---|
| 09:00 – 10:00 EDT | OPENING SESSION Co-Chairs: Nick Drager, TBVI (Switzerland) Mark Feinberg, IAVI (USA) David Lewinsohn, Working Group on New TB Vaccines (USA) Welcome Remarks Global Forum Co-Chairs: Nick Drager, TBVI; Mark Feinberg, IAVI; David Lewinsohn, WGNV Stop TB Partnership: Lucica Ditiu (Switzerland) Keynote Address Honorable Dr. Harsh Vardhan, Union Minister of Health and Family Welfare, Science and Technology and Earth Sciences, Government of India; Chairman, Stop TB Partnership Board (India) Keynote Presentation Helen Rees Wits RHI, Wits University (South Africa) Opening Remarks Emilio A. Emini, Bill & Melinda Gates Foundation (USA) Emily Erbeling, NIAID Division of Microbiology and Infectious Diseases (USA) Michael Makanga, European & Developing Countries Clinical Trials Partnership (Netherlands) |
| 10:00 – 10:15 | BREAK |
| 10:15 – 11:45 | SCIENTIFIC SESSION: NOVEL INSIGHTS AND APPROACHES TO TB VACCINE R&D Co-Chairs: Willem Hanekom, Africa Health Research Institute (South Africa) Huang Huang, Institute for Immunity, Transplantation and Infection, Stanford University (USA) <i>Part 1: Granulomas: Novel insights into an ancient structure</i> Visualizing immunosuppressive microenvironments in <i>Mycobacterium tuberculosis</i> granulomas Michael Gerner, University of Washington, Department of Immunology (USA) Insights into features of bacterial control from single cell profiling of TB granulomas Hannah Priyadarshini Gideon, University of Pittsburgh School of Medicine (USA) <i>Part 2: Novel Insights into protective immunity</i> Vaccination – intended and non-intended consequences Andrea M. Cooper, University of Leicester (UK) Dissecting antibody functions in tuberculosis Lenette Lu, Division of Infectious Diseases and Geographic Medicine, UT Southwestern Medical Center (USA) <i>Part 3: Novel vaccine delivery platform</i> mRNA vaccines against tuberculosis Mustafa Diken, BioNTech (Germany) |
| 11:45 – 12:00 | BREAK |
| 12:00 – 13:30 | SPECIAL SESSION: ACCELERATING TB VACCINE RESEARCH AND DEVELOPMENT: LAUNCH OF A GLOBAL ROADMAP Co-Chairs: Mark Hatherill, South African Tuberculosis Vaccine Initiative (South Africa) Matteo Zignol, Global TB Programme, World Health Organisation (Switzerland) The TB vaccine roadmap: actions and enabling considerations Frank Cobelens, Amsterdam Institute for Global Health and Development (AIGHD) (Netherlands) Opportunities for TB vaccine R&D Willem Hanekom, Africa Health Research Institute (AHRI) (South Africa) A community perspective on the TB vaccine R&D roadmap Blessina Kumar, Global Coalition of TB Activists (India) Panel discussion featuring <ul style="list-style-type: none">• Videlis Nduba, Kenya Medical Research Institute (KEMRI) (Kenya)• Ann Ginsberg, Bill & Melinda Gates Foundation (USA) |

- Birgitte Giersing, Immunization, Vaccines and Biologicals (IVB), World Health Organisation (Switzerland)
- Rajinder Suri, Developing Countries Vaccine Manufacturers Network (DCVMN) (India)
- Agnès Saint-Raymond, European Medicines Agency (EMA) (United Kingdom)

Closing Remarks

Michael Makanga, European & Developing Countries Clinical Trials Partnership (EDCTP) (Netherlands)

This special session is organized by the European & Developing Countries Clinical Trials Partnership (EDCTP) and the Amsterdam Institute for Global Health and Development (AIGHD)

**Wednesday
21 April 2021**

| | |
|----------------------|---|
| 9:00 – 10:30 | SCIENTIFIC SESSION: CLINICAL DEVELOPMENT OF NEW TB VACCINES |
| <i>Format:</i> | <p>Co-Chairs: Ann Ginsberg, Bill & Melinda Gates Foundation (USA) Monde Muyoyeta, Centre for Infectious Disease Research in Zambia (Zambia)</p> <p>Advancing TB vaccine candidates in the clinic Ann Ginsberg, Bill & Melinda Gates Foundation (USA)</p> <p>Update on development activities for M72/AS01_E Alexander Schmidt, Bill & Melinda Gates Medical Research Institute (USA)</p> <p>The DAR-901 prevention of infection trial C. Fordham von Reyn, Dartmouth Geisel School of Medicine (USA)</p> <p>MTBVAC, an attenuated TB vaccine: looking towards the efficacy trial Ingrid Murillo Jelsbak, Biofabri, Zenda Group (Spain)</p> <p>The tuberculosis vaccine H56:IC31 Álvaro Borges, Center for Vaccine Research, Statens Serum Institut (Denmark)</p> <p>A brief update on the VPM1002 vaccine candidate Sajjad Desai, Serum Institute of India Pvt Ltd. (India)</p> <p>From TB to COVID and back again: public involvement as an essential science Anastasia Koch and Cheleka Ann-Marie Mpande, Eh!woza (South Africa)</p> |
| 10:30 – 10:45 | BREAK |
| 10:45 – 11:45 | PANEL DISCUSSION: POLICY AND ACCESS ISSUES FOR TB VACCINES |
| | <p>Co-Chairs: Alejandro Cravioto, Facultad de Medicina, Universidad Nacional Autónoma de México (Mexico) Shelly Malhotra, IAVI (USA)</p> <p>Opening Remarks Stéphanie Seydoux, French Ambassador for Global Health, French Republic</p> <p>Panel Discussion</p> <ul style="list-style-type: none"> • Gagandeep Kang, Christian Medical College (India) • Luciana Leite, Instituto Butantan (Brazil) • Evaline Kibuchi, Stop TB Partnership Kenya (Kenya) • Muhwa Jeremiah Chakaya, London School of Hygiene and Tropical Medicine; Respiratory Society of Kenya (Kenya) • Deepali Patel, Gavi, the Vaccine Alliance (Switzerland) • Cherise Scott, UNITAID (Switzerland) |
| 11:45 – 12:00 | BREAK |
| 12:00 – 13:00 | SPONSORED SESSION: IMPACT OF TB PREVENTIVE TREATMENT (TPT) AS STANDARD OF CARE ON TB VACCINE DEVELOPMENT |
| | <p>Interactive roundtable discussion featuring:</p> <ul style="list-style-type: none"> • Giorghis (George) Belai, FHI Clinical (Kenya) • Falgunee K. Parekh, EpiPointe (USA) • Jon (Ben) Woods, Physician, Pediatric Infectious Disease (USA) • Carole D. Mitnick, Department of Global Health & Social Medicine, Harvard Medical School (USA) <p><i>This session is sponsored and organized by FHI Clinical.</i></p> |

| | |
|----------------------|---|
| 12:00 – 13:30 | WORKSHOP: ADVOCACY FOR RESEARCHERS |
| | <p>What is advocacy and why is it important for researchers to advocate? Uvi Naidoo, Pediatrician (South Africa) David Lewinsohn, Working Group on New TB Vaccines; Oregon Health & Science University (USA)</p> <p>Advocating to governments for policies and funding Evaline Kibuchi, Global TB Caucus Africa Region; Stop TB Partnership Kenya (Kenya) Agustin Martin, DSW (Germany/EU) Nandita Venkatesan (India)</p> <p>Advocating to communities and civil society to increase knowledge and interest Anastasia Koch, Eh!woza (South Africa) Rosa Herrera, Global TB CAB; TB Proof (Mexico)</p> <p>How to communicate scientific findings for advocacy Cheleka Mpande, Eh!Woza; South African Tuberculosis Vaccine Initiative (South Africa) Laia Ruiz Mingote (Spain)</p> <p>Tools for advocacy Rabita Aziz, Infectious Diseases Society of America (USA) Rhea Lobo, Bolo Didi (Denmark)</p> <p><i>This workshop is organized by the Stop TB Partnership Working Group on New TB Vaccines Advocacy Subgroup.</i></p> |

Thursday

22 April 2021

| | |
|----------------------|---|
| 9:00 – 10:30 | SCIENTIFIC SESSION: BCG, 100 YEARS LATER |
| | <p>Co-Chairs: Camille Loch, Inserm; Center for Infection and Immunity of Lille, Institut Pasteur de Lille (France) Puck Teetje Pelzer, KNCV Tuberculosis Foundation (Netherlands)</p> <p>BCG: What have we learnt in 100 years? Helen McShane, The Jenner Institute, University of Oxford (UK)</p> <p>Trained immunity as a mechanism behind the wider applicability of BCG Simone A. Joosten, Department of Infectious Diseases, Leiden University Medical Center (Netherlands)</p> <p>BCG clinical trials for COVID-19 and other respiratory infections Nigel Curtis, The University of Melbourne; Murdoch Children's Research Institute (Australia)</p> <p>BCG revaccination: trial endpoints and potential policy impact Gavin Churchyard, Aurum Institute (South Africa)</p> <p>Potential effect of disruptions to BCG vaccination on global paediatric tuberculosis mortality Richard G. White, Centre for the Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine (UK)</p> |
| 10:30 – 10:45 | BREAK |
| 10:45 – 11:45 | PANEL DISCUSSION: LEVERAGING COVID-19 TO ADVANCE TO VACCINE R&D |
| | <p>Co-Chairs: Gerald Voss, TBVI (Belgium) Julio Croda, Oswaldo Cruz Foundation; School of Medicine, Federal University of Mato Grosso do Sul (Brazil)</p> <p>Panel Discussion</p> <ul style="list-style-type: none"> • Valerie Oriol Mathieu, Janssen Infectious Diseases and Vaccines (Netherlands) • Nicole Lurie, Coalition for Epidemic Preparedness Innovations (UK) • Jim Kublin, HVTN; Fred Hutchinson Cancer Research Center (USA) • Erica Andersen-Nissen, Cape Town HVTN Immunology Laboratory (South Africa) • Gordon Dougan, Wellcome Sanger Institute (UK) • Hassan Mahomed, Stellenbosch University (South Africa) |
| 11:45 – 12:00 | BREAK |
| 12:00 – 13:00 | PANEL DISCUSSION: CLOSING THE FINANCING GAP FOR TB VACCINE R&D |
| | <p>Co-Chairs: Glaudina Loots, Department of Science and Technology (South Africa) Mike Frick, Treatment Action Group (USA)</p> <p>Panel Discussion</p> <ul style="list-style-type: none"> • Shiva Dustdar, European Investment Bank (Luxembourg) |

| | |
|-----------------------|---|
| | <ul style="list-style-type: none"> • Manjula Singh, Indian Council on Medical Research (India) • Lucica Ditiu, Stop TB Partnership (Switzerland) • Nicolas Menzies, Harvard T.H. Chan School of Public Health (USA) • Hon. Dr. Sibongiseni Dhlomo, National Assembly in Parliament; National TB Caucus (South Africa) |
| 13:00 – 13 :30 | CLOSING SESSION |
| | <p>Co-Chairs: Co-Chairs: Nick Drager, TBVI (Switzerland) Mark Feinberg, IAVI (USA) David Lewinsohn, Working Group on New TB Vaccines (USA)</p> <p>Closing Remarks Eric Goosby, UCSF Gladstone Center for AIDS Research; UN Secretary-General’s Special Envoy on Tuberculosis, (USA)</p> <p>Closing Address Soumya Swaminathan, World Health Organization (Switzerland)</p> <p>Remarks from 6th Global Forum Host Country Mr. Olivier Véran, Minister for Solidarity and Health, French Republic</p> |